Abstract
New series of catechol ether type derivatives5, 6 have been synthesized and applied to biological test. Even though it is a preliminary data, some of our target molecules show the promising result against PDE IV inhibition. SAR and biological studies with synthetic compounds will be discussed in detail.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References Cited
Ashton, M. J., Cook, D. C., Fenton, G., Karlsson, J. A., Palfreyman, M. N., Raeburn, D., Ratcliffe, A. J., Souness, J. E., Thurairatnam, S. and Vicker, N., Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues.J. Med. Chem., 37, 1696–1703 (1994).
Barnette, M. S., Grous, M., Cieslinski, L. B., Burman, M., Christensen, S. B. and Torphy, T. J., Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site.J. Pharmacol. Exp. Ther., 273, 1396–1402 (1995).
Beavo, J. A., Conti, M. and Heaslip, R. J., Multiple cyclic nucleotide phosphodiesterases.Mol. Pharmacol., 46, 399–405 (1994).
Beavo, J. A. and Reifsnyder, D. H., Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors.Trends Pharmacol. Sci., 11, 150–155 (1990).
Christensen, S. B., Guider, A., Forster, C. J., Gleason, J. G., Bender, P. E., Karpinski, J. M., DeWolf, W. E. Jr., Barnette, M. S., Underwood, D. C., Griswold, D. E., Cieslinski, L. B., Burman, M., Bochnowicz, S., Osborn, R. R., Manning, C. D., Grous, M., Hillegas, L. M., Bartus, J. O., Ryan, M. D., Eggleston, D. S., Haltiwanger, R. C. and Torphy, T. J., 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma.J. Med. Chem., 41, 821–835 (1998).
Cohan, V. L., Showell, H. J., Pettipher, E. R., Fisher, D. A., Pazzoles, C. J., Watson, J. W., Turner, C. R. and Cheng, J. B.,In vitro pharmacology of the novel type IV phosphodiesterase (PDEIV) inhibitor, CP-80,633.J. Allergy Clin. Immunol., 95, 350 (1995) [Abstract].
Cortijo, J., Bou, J., Beleta, J., Cardelus, I., Llenas, J., Motciool, E. and Gristwood, R. W., Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus.Br. J. Pharmacol., 108, 562–56 (1993).
Erneux, C., Van Sande, J., Milot, F., Cochaux, P., Decosster, C. and Dumont, J. E., A mechanism in the control of intracellular cAMP level: the activation of a calmodulin-sensitive phosphodiesterase by a rise of intracellular free calcium.Mol. Cell. Endocrinol., 43, 123–134 (1985).
Holbrook, M., Gozzard, N., James, T., Higgs, G. and Hughes, B., Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guineapig by CDP840, a novel phosphodiesterase type 4 inhibitor.Br. J. Pharmacol., 118, 1192–1200 (1996).
Kammer, G. M., The adenylate cyclase-cAMP-protein kinase pathway and regulation of immune response.Immunol. Today 9, 222–229 (1988).
Lynch, J. E., Choi, W.-B., Churchill, H. R. O., Volante, R. P., Reamer, R. A. and Ball, R. G., Asymmetric synthesis of CD840 by Jacobsen Epoxidation. An usual Syn selective reduction of an epoxide.J. Org. Chem., 62, 9223–9228 (1997).
Marivet, M. C., Bourguignon, J.-J., Lugnier, C., Mann, A., Stoclet, J.-C. and Wermuth, C., Inhibition of cyclic adenosine-3′,5′-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues.J. Med. Chem., 32, 1450–1457 (1989).
Nicholson, C., Challis, R. and Shakio, M., Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes.Trends Pharmacol. Sci., 12, 19–27 (1991).
Schmiechen, R., Schneider, H. H. and Watchtel, H., Close correlation between behavioral response and bindingin vivo for inhibitors of the rolipram-sensitive phosphodiesterase.Psychopharmacology, 102, 17–20 (1990).
Torphy, T. J. and Undem, B. J., Phosphodiesterase inhibitors: New opportunities for the treatment of asthma.Thorax 46, 512–523 (1991).
Smellie, A., Teig, S. L. and Towbin, P., “Poling: Promoting Conformational Coverage”.J. Comp. Chem., 16, 171–187 (1995).
Weishaar, R. E., Cain, M. H. and Bristol, J. A., A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.J. Med. Chem., 28, 537–545 (1985).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rhee, C.K., Kim, J.H., Sub, BC. et al. Synthesis and biological studies of catechol ether type derivatives as potential phosphodiesterase (PDE) IV inhibitors. Arch Pharm Res 22, 202–207 (1999). https://doi.org/10.1007/BF02976547
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02976547